Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NASDAQ:ERNA NASDAQ:GELS NASDAQ:QLGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.46-4.3%$2.57$7.96▼$24.15$12.41M0.6315,685 shs10,797 shsERNAErnexa Therapeutics$1.51-0.7%$1.91$1.48▼$28.80$11.58M5.42302,840 shs70,617 shsGELSGelteq$1.29+2.4%$1.71$0.77▼$5.50$12.18MN/A1.21 million shs20,274 shsQLGNQualigen Therapeutics$1.84+0.5%$2.87$1.61▼$10.50$3.13M-0.17367,961 shs7,493 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir0.00%+12.72%+7.53%-9.19%-85.48%ERNAErnexa Therapeutics-1.94%-6.17%-24.38%-55.56%-94.37%GELSGelteq-5.97%-11.27%-35.38%-30.00%+125,999,900.00%QLGNQualigen Therapeutics-1.59%+5.40%-38.17%-50.80%-81.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AERNAErnexa Therapeutics0.3826 of 5 stars0.03.00.00.01.21.70.0GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AERNAErnexa Therapeutics 0.00N/AN/AN/AGELSGelteq 0.00N/AN/AN/AQLGNQualigen Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AERNAErnexa Therapeutics$580K19.97N/AN/A$0.58 per share2.60GELSGelteq$100K121.78N/AN/A$1.30 per share0.99QLGNQualigen Therapeutics$4.98M0.63N/AN/A($2.62) per share-0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)ERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-682.08%11/10/2025 (Estimated)GELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/AQLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%N/ALatest QLGN, ALVR, ERNA, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A8/13/2025Q2 2025ERNAErnexa TherapeuticsN/A-$0.61N/A-$0.61N/AN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78ERNAErnexa TherapeuticsN/A1.811.81GELSGelteqN/A0.79N/AQLGNQualigen TherapeuticsN/A0.711.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%ERNAErnexa Therapeutics70.55%GELSGelteqN/AQLGNQualigen Therapeutics3.18%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%ERNAErnexa Therapeutics1.50%GELSGelteqN/AQLGNQualigen Therapeutics1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableERNAErnexa Therapeutics107.67 million7.56 millionNo DataGELSGelteqN/A9.44 millionN/AN/AQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableQLGN, ALVR, ERNA, and GELS HeadlinesRecent News About These CompaniesQualigen Therapeutics, Inc.: Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 30, 2025 | finanznachrichten.deQualigen Therapeutics Announces $4.5M Private PlacementJuly 29, 2025 | msn.comQualigen Therapeutics provides update on Nasdaq listing statusJuly 28, 2025 | msn.comQualigen Therapeutics Secures Nasdaq Compliance ExtensionJuly 28, 2025 | msn.comQualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing StatusJuly 28, 2025 | finance.yahoo.comQualigen Therapeutics, Inc. Secures $4.5 Million Through Series A-3 Preferred Stock Private PlacementJuly 28, 2025 | quiverquant.comQQualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred StockJuly 28, 2025 | globenewswire.comQualigen Granted New Patents Covering 25 CountriesJuly 16, 2025 | manilatimes.netMQualigen Therapeutics shares surge after patent approvals in 25 countriesJuly 16, 2025 | msn.comQualigen Therapeutics, Inc. (QLGN) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comQualigen Therapeutics faces potential Nasdaq delistingMay 21, 2025 | uk.investing.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...May 19, 2025 | gurufocus.comQualigen Therapeutics Faces Nasdaq Delisting NotificationMay 19, 2025 | tipranks.comQualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing DeficiencyMay 19, 2025 | quiverquant.comQQualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-QMay 19, 2025 | globenewswire.comMarizyme, Inc. (MRZM) Latest Press Releases & Corporate News - Yahoo FinanceMay 10, 2025 | finance.yahoo.comQualigen Therapeutics Faces Nasdaq Delisting ThreatMay 1, 2025 | tipranks.comQualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-KMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Why the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Global Value: 3 Stocks Under $10 Riding a Weak DollarBy Chris Markoch | July 30, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025QLGN, ALVR, ERNA, and GELS Company DescriptionsAlloVir NASDAQ:ALVR$2.46 -0.11 (-4.28%) As of 08/21/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Ernexa Therapeutics NASDAQ:ERNA$1.51 -0.01 (-0.66%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Gelteq NASDAQ:GELS$1.29 +0.03 (+2.38%) As of 02:59 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Qualigen Therapeutics NASDAQ:QLGN$1.84 +0.01 (+0.55%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Broadcom Named in Apple’s $100B U.S. Investment Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access